Kenvue (NYSE:KVUE) Upgraded at Wall Street Zen

Kenvue (NYSE:KVUE) was upgraded by research analysts at Wall Street Zen to a “buy” rating in a report issued on Sunday.

KVUE has been the topic of several other reports. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays dropped their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. UBS Group cut their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Citigroup decreased their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Three investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Stock Performance

NYSE:KVUE traded up $0.32 during trading hours on Friday, hitting $19.50. 9,451,469 shares of the company were exchanged, compared to its average volume of 18,740,484. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. Kenvue has a 52-week low of $14.02 and a 52-week high of $22.87. The stock has a market capitalization of $37.43 billion, a price-to-earnings ratio of 22.94, a PEG ratio of 1.48 and a beta of 0.47. The company’s 50 day moving average price is $18.06 and its 200-day moving average price is $17.79.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter last year, the company posted $0.24 earnings per share. The business’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, research analysts forecast that Kenvue will post 1.16 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.59% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kenvue

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Butensky & Cohen Financial Security Inc. increased its holdings in shares of Kenvue by 8.1% during the 2nd quarter. Butensky & Cohen Financial Security Inc. now owns 248,588 shares of the company’s stock valued at $4,751,000 after purchasing an additional 18,627 shares in the last quarter. Tema ETFs LLC grew its position in Kenvue by 10.8% during the second quarter. Tema ETFs LLC now owns 38,784 shares of the company’s stock valued at $741,000 after buying an additional 3,770 shares during the period. Canvas Wealth Advisors LLC increased its holdings in Kenvue by 16.3% in the second quarter. Canvas Wealth Advisors LLC now owns 31,677 shares of the company’s stock valued at $605,000 after buying an additional 4,434 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Kenvue by 6.5% in the second quarter. Handelsbanken Fonder AB now owns 1,138,036 shares of the company’s stock valued at $21,748,000 after buying an additional 69,659 shares in the last quarter. Finally, HF Advisory Group LLC raised its position in shares of Kenvue by 8.4% in the second quarter. HF Advisory Group LLC now owns 259,626 shares of the company’s stock worth $4,961,000 after acquiring an additional 20,080 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.